J F C Pedrazzi1, A C Issy, F V Gomes, F S Guimarães, E A Del-Bel. 1. Departamento de Morfologia, Estomatologia e Patologia Básica, Faculdade de Odontologia, Universidade de São Paulo, Ribeirão Preto, SP, 14049-904, Brasil.
Abstract
RATIONALE: The information processing appears to be deficient in schizophrenia. Prepulse inhibition (PPI), which measures the inhibition of a motor response by a weak sensory event, is considered particularly useful to understand the biology of information processing in schizophrenia patients. Drugs that facilitate dopaminergic neurotransmission such as amphetamine induce PPI disruption in human and rodents. Clinical and neurobiological findings suggest that the endocannabinoid system and cannabinoids may be implicated in the pathophysiology and treatment of schizophrenia. Cannabidiol (CBD), a non-psychotomimetic constituent of the Cannabis sativa plant, has also been reported to have potential as an antipsychotic. OBJECTIVE: Our aim was to investigate if CBD pretreatment was able to prevent PPI disruption induced by amphetamine. Since one possible mechanism of CBD action is the facilitation of endocannabinoid-mediated neurotransmission through anandamide, we tested the effects of an anandamide hydrolysis inhibitor (URB597) in the amphetamine-induced PPI disruption. METHODS: Male Swiss mice were treated with CBD systemic or intra-accumbens, or URB597 (systemic) prior to amphetamine and were exposed to PPI test. RESULTS: Amphetamine (10 mg/kg) disrupted PPI while CBD (15-60 mg/kg) or URB597 (0.1-1 mg/kg) administered alone had no effect. Pretreatment with CBD attenuated the amphetamine-disruptive effects on PPI test after systemic or intra-accumbens administration. Similar effects were also found with the inhibitor of anandamide hydrolysis. CONCLUSION: These results corroborate findings indicating that CBD induces antipsychotic-like effects. In addition, they pointed to the nucleus accumbens as a possible site of these effects. The increase of anandamide availability may be enrolled in the CBD effects.
RATIONALE: The information processing appears to be deficient in schizophrenia. Prepulse inhibition (PPI), which measures the inhibition of a motor response by a weak sensory event, is considered particularly useful to understand the biology of information processing in schizophreniapatients. Drugs that facilitate dopaminergic neurotransmission such as amphetamine induce PPI disruption in human and rodents. Clinical and neurobiological findings suggest that the endocannabinoid system and cannabinoids may be implicated in the pathophysiology and treatment of schizophrenia. Cannabidiol (CBD), a non-psychotomimetic constituent of the Cannabis sativa plant, has also been reported to have potential as an antipsychotic. OBJECTIVE: Our aim was to investigate if CBD pretreatment was able to prevent PPI disruption induced by amphetamine. Since one possible mechanism of CBD action is the facilitation of endocannabinoid-mediated neurotransmission through anandamide, we tested the effects of an anandamide hydrolysis inhibitor (URB597) in the amphetamine-induced PPI disruption. METHODS: Male Swiss mice were treated with CBD systemic or intra-accumbens, or URB597 (systemic) prior to amphetamine and were exposed to PPI test. RESULTS:Amphetamine (10 mg/kg) disrupted PPI while CBD (15-60 mg/kg) or URB597 (0.1-1 mg/kg) administered alone had no effect. Pretreatment with CBD attenuated the amphetamine-disruptive effects on PPI test after systemic or intra-accumbens administration. Similar effects were also found with the inhibitor of anandamide hydrolysis. CONCLUSION: These results corroborate findings indicating that CBD induces antipsychotic-like effects. In addition, they pointed to the nucleus accumbens as a possible site of these effects. The increase of anandamide availability may be enrolled in the CBD effects.
Authors: Felipe V Gomes; Plinio C Casarotto; Leonardo B M Resstel; Francisco S Guimarães Journal: Prog Neuropsychopharmacol Biol Psychiatry Date: 2010-11-25 Impact factor: 5.067
Authors: C D Schubart; I E C Sommer; P Fusar-Poli; L de Witte; R S Kahn; M P M Boks Journal: Eur Neuropsychopharmacol Date: 2013-11-15 Impact factor: 4.600
Authors: Raquel Levin; Fernanda F Peres; Valéria Almeida; Mariana B Calzavara; Antonio W Zuardi; Jaime E C Hallak; José Alexandre S Crippa; Vanessa C Abílio Journal: Front Pharmacol Date: 2014-02-06 Impact factor: 5.810
Authors: João F C Pedrazzi; Frederico R Ferreira; Danyelle Silva-Amaral; Daniel A Lima; Jaime E C Hallak; Antônio W Zuardi; Elaine A Del-Bel; Francisco S Guimarães; Karla C M Costa; Alline C Campos; Ana C S Crippa; José A S Crippa Journal: Psychopharmacology (Berl) Date: 2022-07-29 Impact factor: 4.415
Authors: Christopher Norris; Michael Loureiro; Cecilia Kramar; Jordan Zunder; Justine Renard; Walter Rushlow; Steven R Laviolette Journal: Neuropsychopharmacology Date: 2016-06-14 Impact factor: 7.853
Authors: Aviva Breuer; Christeene G Haj; Manoela V Fogaça; Felipe V Gomes; Nicole Rodrigues Silva; João Francisco Pedrazzi; Elaine A Del Bel; Jaime C Hallak; José A Crippa; Antonio W Zuardi; Raphael Mechoulam; Francisco S Guimarães Journal: PLoS One Date: 2016-07-14 Impact factor: 3.240
Authors: Uma Suryadevara; Dawn M Bruijnzeel; Meena Nuthi; Darin A Jagnarine; Rajiv Tandon; Adriaan W Bruijnzeel Journal: Curr Neuropharmacol Date: 2017 Impact factor: 7.363
Authors: Alline C Campos; Manoela V Fogaça; Franciele F Scarante; Sâmia R L Joca; Amanda J Sales; Felipe V Gomes; Andreza B Sonego; Naielly S Rodrigues; Ismael Galve-Roperh; Francisco S Guimarães Journal: Front Pharmacol Date: 2017-05-23 Impact factor: 5.810
Authors: Fernanda F Peres; Raquel Levin; Valéria Almeida; Antonio W Zuardi; Jaime E Hallak; José A Crippa; Vanessa C Abilio Journal: Front Pharmacol Date: 2016-09-09 Impact factor: 5.810